Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity

June 12, 2026 updated by: Jacqueline K Limberg, PhD, University of Missouri-Columbia
In the present study, we seek to determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

64

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Missouri
      • Columbia, Missouri, United States, 65211
        • University of Missouri
        • Contact:
        • Principal Investigator:
          • Jacqueline Limberg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18 to 65 years of age

Individuals with obesity and comorbid IR

  • BMI 30-45 kg/m2
  • Waist circumference ≥102 cm (men) or ≥88 cm (women)
  • HOMA-IR ≥2.5

Healthy normal weight adults

  • BMI 18-25 kg/m2
  • Waist circumference <94 cm (men) and <80 cm (women)
  • HOMA-IR <2

Exclusion Criteria:

  • Pregnancy, breastfeeding
  • Unable to provide consent
  • Diabetes or polycystic ovarian syndrome
  • Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke
  • Nerve/neurologic disease
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg)
  • Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
  • Current smoking, tobacco, nicotine use
  • Use of pharmacological therapy for weight loss
  • Body weight change >10% within the last 6 months
  • Adherence to >150 min/week of moderate-to-vigorous physical activity/exercise
  • Participation in any other research study or medical procedure involving significant ionizing radiation exposure in the past 12 months
  • Claustrophobia
  • Non-MRI compatible metal implants

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Insulin (Doppler)
Human insulin (160 IU) will be administered using an intra-nasal device
Drug: human insulin
Participants will be administered human insulin (160 IU) using an intra-nasal device.
Experimental: Insulin (MRI)
Human insulin (160 IU) will be administered using an intra-nasal device.
Drug: human insulin
Participants will be administered human insulin (160 IU) using an intra-nasal device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amount of muscle sympathetic nerve activity (MSNA)
Time Frame: Change from baseline at minute 30
MSNA burst incidence (bursts/100 heart beats)
Change from baseline at minute 30
Amount of cerebral blood flow
Time Frame: Change from baseline at minute 30
Measured with arterial spin labeling (mL/100 g/min)
Change from baseline at minute 30
Amount of leg blood flow
Time Frame: Change from baseline at minute 30
Measured with Doppler ultrasound (mL/min)
Change from baseline at minute 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Missouri-Columbia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

June 1, 2031

Study Completion (Estimated)

June 1, 2032

Study Registration Dates

First Submitted

June 12, 2026

First Submitted That Met QC Criteria

June 12, 2026

First Posted (Actual)

June 17, 2026

Study Record Updates

Last Update Posted (Actual)

June 17, 2026

Last Update Submitted That Met QC Criteria

June 12, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2134707

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Insulin Resistance

Clinical Trials on human insulin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe